Pharmaceuticals, Biotechnology and Life Sciences
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, intends to join the AIM market of the London Stock Exchange by way of a Placing to raise approximately £5 million.
FDA allows Avita to expand its Compassionate Use Investigational Device Exemption (IDE) program for ReCell.
Vectura’s partner on the VR876 programme has achieved an important development milestone in Europe, which triggered a cash milestone payment of €5m (circa. £3.6m) to Vectura.
Vernalis plc has announces that it has acquired the US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (“Pragma”).
Bayer has announced that from September 30th to October first, Bayer CropScience is hosting over 175 industry professionals from over 15 different countries at its Horticulture Symposium in Puerto Vallarta, Mexico.
Allergan has completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel…
Teva Pharmaceutical Industries Ltd., has announced that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b…
Novartis announced on Wednesday that results from the pivotal Phase III FUTURE 1 study for Secukinumab in psoriatic arthritis (PsA)…
Sanofi announced on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lixisenatide.
ImmuPharma PLC the specialist drug discovery and development company, has announced the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.